Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
Scientists have determined unexpected characteristics of a key protein linked to blood pressure control and to nerve growth, pain control and heart tissue regeneration. The findings, published April 5 online in the journal Nature, opens doors to potential new therapies to control cardiovascular disease and pain.
Researchers hope to design a new generation of drugs against an array of deadly diseases. The task, however, is costly, arduous and often ineffective. One of the key challenges is understanding a particular class of proteins adorning cell surfaces, which are the targets of the majority of pharmaceutical drugs.
Heart failure patients who are getting by on existing drug therapies can look forward to a far more effective medicine in the next five years or so, thanks to University of Alberta researchers.
Mothers contribute a lot of defining traits to their offspring, from eye color to toe length. But pregnant mothers with health complications, such as diabetes or hypertension, also can pass these symptoms to their children.
A two-drug cocktail provided better protection against diabetes-related vision loss than a single drug during testing in rat models, a team of University of Florida Health and Dutch researchers has found.
Results of a new study led by Johns Hopkins researchers offer new evidence for a strong link between angiotensin receptor autoantibodies and increased risk of frailty.
The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2016, November 15-20 at McCormick Place in Chicago, IL.
To improve care for patients with kidney dysfunction, investigators are striving to identify modifiable risk factors that may slow the progression of chronic kidney disease (CKD) to kidney failure.
The academic partners in the VerICiguaT GlObal Study in Subjects with Heart Failure with Reduced EjectIon FrAction are pleased to announce that patient enrollment has begun.
Medications prescribed to prevent heart attacks such as statins and aspirin are also associated with reduced heart attack severity, according to research published in PLOS ONE.
The European Society of Cardiology has launched a novel position paper, under the auspices of its Committee for Practice Guidelines, on tackling the cardiac toxicity of anticancer therapies. The cardio-oncology paper is published online today in European Heart Journal and on the ESC Website.
Among U.S. adults with diabetes from 1988 to 2014, the overall prevalence of diabetic kidney disease did not change significantly, while the prevalence of albuminuria declined and the prevalence of reduced estimated glomerular filtration rate increased, according to a study appearing in the August 9 issue of JAMA.
With cardiovascular disease being the No. 1 cause of death in end-stage kidney disease patients on peritoneal dialysis, a new study examined two classes of medications commonly prescribed to prevent cardiovascular events in these patients and found no significant difference in outcomes.
Researchers today unveiled results from a new blood test to help identify which patients are at an elevated risk of Alzheimer's disease.
Silvergate Pharmaceuticals, Inc., leader in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Qbrelis (Lisinopril) Oral Solution, the first and only FDA-approved Lisinopril oral solution.
New research by University of Iowa scientists helps explain how a hormone system often targeted to treat cardiovascular disease can also lower metabolism and promote obesity.
In the current issue of Psychotherapy and Psychosomatics, the relationship of drugs that are generally used for treating hypertension (angiotensin converting enzyme inhibitors) are examined in their effects as to depression.
A new online open-access database has been developed by scientists to allow the clinical responses of more than 5 million patients to all FDA-approved drugs to be used to identify unexpected clinical harm, benefits and alternative treatment choices for individual patients, according to a study appearing July 8 in Nature Biotechnology.
A UCLA-led study estimates that almost 28,500 deaths could be prevented each year in the U.S. through use of a new FDA-approved class of cardiovascular medication that helps reduce mortality in patients diagnosed with heart failure and reduced ejection fraction, the percentage of blood pumped from the heart with each contraction.
Two classes of blood pressure medications, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), are associated with a 16% lower risk of strokes, heart attacks and death in patients with end-stage renal disease who are undergoing peritoneal dialysis, a new study in the journal, Nephrology Dialysis Transplantation, reports.